Doliprane: The French Medicine in Crisis and State Intervention

Monday, 14 October 2024, 18:00

Doliprane has become a focal point of contention as workers demand that this essential medication must remain French. The state faces pressure regarding interventions. Amid negotiations for the sale of Sanofi's Doliprane to an American investment fund, the government is navigating these growing tensions and assuring employees of support.
Francetvinfo
Doliprane: The French Medicine in Crisis and State Intervention

Doliprane's Future and Government Response

In Lisieux (Calvados), Sanofi employees are on strike, advocating that Doliprane must remain a French product. They want the government to block the sale of their operations to an American investment fund currently in exclusive negotiations. The government is attempting to soothe employee fears, with an emergency visit from the Minister of Economy aimed at resolving the situation and sending a clear message: the state will not abandon the workers.

Foreign Investments in France

On Monday afternoon, October 14, Emmanuel Macron emphasized that this issue pertains to sovereignty. What can the state actually do? In France, foreign investments are typically free, except in certain sensitive sectors like defense, water, or food where prior authorization from Bercy is required. Refusals are quite rare. Typically, the state negotiates compensation, which businesses are keen to accept. Failure to honor agreements can lead to significant sanctions.

For the full report, watch the video above.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest insights and trends from around the world. Stay informed and elevate your global perspective effortlessly.

Subscribe